We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

68 hedge funds and large institutions have $489M invested in Eagle Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 5

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

243% more capital invested

Capital invested by funds: $143M → $489M (+$347M)

143% more funds holding

Funds holding: 28 → 68 (+40)

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

Holders
68
Holders Change
+40
Holders Change %
+142.86%
% of All Funds
1.81%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.13%
New
45
Increased
13
Reduced
8
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JHIU
Janus Henderson Investors US
Colorado
+$22.3M
2
CCM
Consonance Capital Management
New York
+$20.9M
3
JAM
JW Asset Management
Florida
+$18M
4
CAM
Cormorant Asset Management
Massachusetts
+$8.98M
5
Morgan Stanley
Morgan Stanley
New York
+$5.42M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$10.7M
2
GE
General Electric
Ohio
-$6.06M
3
PWAM
Park West Asset Management
California
-$4.97M
4
DM
Deerfield Management
New York
-$4.41M
5
TAM
THB Asset Management
Connecticut
-$4.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$1.44M +$972K +34,251 New
BIT
27
BlackRock Institutional Trust
California
$1.36M +$923K +32,533 New
BCM
28
Bridgeway Capital Management
Texas
$1.34M – – –
Bank of New York Mellon
29
Bank of New York Mellon
New York
$1.31M +$887K +31,276 New
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$1.27M +$80.6K +2,842 +10%
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$1.25M +$844K +29,742 New
CSS
32
Cubist Systematic Strategies
Connecticut
$1.09M +$737K +25,972 New
ECM
33
Endurant Capital Management
California
$1.07M +$723K +25,500 New
PP
34
PDT Partners
New York
$1.03M +$696K +24,527 New
SLG
35
Stanley-Laman Group
Pennsylvania
$1M -$3.09M -108,790 -82%
TC
36
TFS Capital
Pennsylvania
$953K +$645K +22,752 New
SAM
37
Sectoral Asset Management
Quebec, Canada
$927K +$628K +22,123 New
GCP
38
GSA Capital Partners
United Kingdom
$901K +$610K +21,500 New
Barclays
39
Barclays
United Kingdom
$820K +$567K +20,000 New
Ameriprise
40
Ameriprise
Minnesota
$781K +$529K +18,652 New
DC
41
Deere & Company
Illinois
$604K +$409K +14,425 New
CS
42
Credit Suisse
Switzerland
$602K +$408K +14,377 New
PAM
43
Panagora Asset Management
Massachusetts
$507K +$343K +12,099 New
PA
44
Perceptive Advisors
New York
$506K +$343K +12,088 New
KIA
45
Kopp Investment Advisors
Minnesota
$500K +$338K +11,925 New
Northern Trust
46
Northern Trust
Illinois
$424K +$287K +10,127 New
Goldman Sachs
47
Goldman Sachs
New York
$412K +$279K +9,839 New
BFA
48
BlackRock Fund Advisors
California
$372K +$160K +5,645 +175%
CAM
49
ClariVest Asset Management
California
$360K -$128K -4,500 -34%
AQR Capital Management
50
AQR Capital Management
Connecticut
$356K +$241K +8,500 New
1
2
3

EGRX Hedge Fund Activity: Q1 2015 in Review

68 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2015, worth a combined $489M — up 243% from $143M a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new EGRX positions and 5 closed out — a net gain of 40 holders — while 13 added to existing stakes and 8 trimmed.

The largest buyer was Janus Henderson Investors US, opening a new position worth an estimated $22.3M. The largest seller was Jennison Associates, exiting entirely with an estimated $10.7M sold.

  • 68 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2015, up from 28 in Q4 2014.
  • Funds reported $489M of Eagle Pharmaceuticals, Inc. stock for Q1 2015, up 243% quarter-over-quarter.
  • 45 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2015 and 5 closed out, a net change of +40 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q1 2015 was Janus Henderson Investors US, an estimated $22.3M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q1 2015 was Jennison Associates, an estimated $10.7M sold.

Based on aggregated 13F filings for Q1 2015.